J&J said it plans to “explore future development opportunities for aticaprant in other areas of high unmet need”. A statement ...

Major depressive disorder (MDD) is a serious mental health condition that impacts individuals of all ages, including children ...

Incorporating dynamic pricing into cost-effectiveness analysis could offer significant benefits for equity in health care.

JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033.

Johnson & Johnson has added to the opioid kappa blues. Months after Neumora reported a phase 3 flop, J&J has stopped ...

NetraMark's first presentation, " Novel Machine Learning Approach Outperforms Traditional Approaches in Major Depressive Disorder Clinical Trials", demonstrated how NetraAI Sub-Insight Learning ...

When I told my mom that I was doing this, we were talking about just how I used the fire spinning as a way to deal with my depression and everything. And that often times when I was more depressed ...

Johnson & Johnson is ending the phase 3 VENTURA clinical development program evaluating aticaprant, a selective kappa receptor antagonist, as an adjunctive treatment for major depressive disorder (MDD ...

On or about September 15, 2023, Neumora conducted the IPO and raised more than $250 million from the investing public. The lawsuit alleges that, unbeknownst to investors, Neumora's KOASTAL-1 study, ...

After failing to hit the primary endpoint in a Phase III trial, Neumora is remixing study parameters in two replicate trials, ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

“The positive data from our MM120 Phase 2b study in GAD helped secure breakthrough therapy designation from the FDA and led to the expansion of our pipeline into MDD. In 2025, we are focused on ...